利妥昔单抗治疗系统性硬化症的前瞻性队列研究
基于EUSTAR网络的前瞻性研究,纳入254例接受利妥昔单抗治疗的SSc患者并与9575例倾向评分匹配的未治疗患者比较。中位随访2年,约70%患者无副作用,治疗组皮肤纤维化改善率更高,但肺功能下降无显著差异,且更易减少或停用激素。
要点
- 利妥昔单抗在SSc中安全性良好,约70%患者无副作用。
- 治疗组皮肤纤维化改善事件率高于对照组(22.7 vs 14.03/100人年)。
- 肺纤维化恶化率与对照组无显著差异,激素减停更常见。
核心结论
- 利妥昔单抗在大型SSc队列中安全性良好,与皮肤纤维化改善相关,但对肺纤维化无显著影响,需随机试验验证。
研究设计与样本
- 前瞻性研究,纳入EUSTAR网络SSc患者,接受利妥昔单抗治疗者与倾向评分匹配的未治疗患者比较。
主要发现
- 254例接受利妥昔单抗治疗,58%因肺受累、32%因皮肤受累。
- 中位随访2年,约70%患者无副作用。
- 匹配9575例对照,治疗组皮肤纤维化改善OR 2.79(95%CI 1.47-5.32;p=0.002)。
- FVC下降>10%的OR 1.03(95%CI 0.55-1.94;p=0.93),DLCO下降无显著差异。
- 治疗组更易停用或减少激素(OR 2.34,95%CI 1.56-3.53;p<0.0001)。
关键数值与推荐
- 皮肤纤维化改善事件率:治疗组22.7 vs 对照组14.03/100人年。
- FVC下降>10%的OR 1.03(95%CI 0.55-1.94;p=0.93)。
- 停用或减少激素的OR 2.34(95%CI 1.56-3.53;p<0.0001)。
- 合并霉酚酸酯患者与单用利妥昔单抗比较:delta FVC 5.22(95%CI 0.83-9.62;p=0.019)vs 3(95%CI 0.66-5.35;p=0.012)。
临床怎么用
- 利妥昔单抗可用于SSc患者,尤其皮肤受累者,安全性良好且有助于激素减量。
- 对肺纤维化进展的稳定作用尚需随机对照试验证实。
局限性
- 观察性设计,存在混杂偏倚可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the safety and efficacy of rituximab in systemic sclerosis (SSc) in clinical practice. METHODS: We performed a prospective study including patients with SSc from the European Scleroderma Trials and Research (EUSTAR) network treated with rituximab and matched with untreated patients with SSc. The main outcomes measures were adverse events, skin fibrosis improvement, lung fibrosis worsening and steroids use among propensity score-matched patients treated or not with rituximab. RESULTS: 254 patients were treated with rituximab, in 58% for lung and in 32% for skin involvement. After a median follow-up of 2 years, about 70% of the patients had no side effect. Comparison of treated patients with 9575 propensity-score matched patients showed that patients treated with rituximab were more likely to have skin fibrosis improvement (22.7 vs 14.03 events per 100 person-years; OR: 2.79 [1.47-5.32]; p=0.002). Treated patients did not have significantly different rates of decrease in forced vital capacity (FVC)>10% (OR: 1.03 [0.55-1.94]; p=0.93) nor in carbon monoxide diffusing capacity (DLCO) decrease. Patients having received rituximab were more prone to stop or decrease steroids (OR: 2.34 [1.56-3.53], p<0.0001). Patients treated concomitantly with mycophenolate mofetil had a trend for better outcomes as compared with patients receiving rituximab alone (delta FVC: 5.22 [0.83-9.62]; p=0.019 as compared with controls vs 3 [0.66-5.35]; p=0.012). CONCLUSION: Rituximab use was associated with a good safety profile in this large SSc-cohort. Significant change was observed on skin fibrosis, but not on lung. However, the limitation is the observational design. The potential stabilisation of lung fibrosis by rituximab has to be addressed by a randomised trial.
引用
- Elhai M, Boubaya M, Distler O, et al. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis. 2019. PMID: 30967395. doi:10.1136/annrheumdis-2018-214816
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。